Increasing CSF phospho-tau levels during cognitive decline and progression to dementia

[1]  K. Blennow,et al.  Differential CSF Biomarker Levels in APOE-ε4-Positive and -Negative Patients with Memory Impairment , 2006, Dementia and Geriatric Cognitive Disorders.

[2]  J. Jolles,et al.  Ten-year risk of dementia in subjects with mild cognitive impairment , 2006, Neurology.

[3]  O. Almkvist,et al.  Identifying Patients at High and Low Risk of Cognitive Decline Using Rey Auditory Verbal Learning Test among Middle-Aged Memory Clinic Outpatients , 2006, Dementia and Geriatric Cognitive Disorders.

[4]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[5]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[6]  Z. Stelmasiak,et al.  The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis , 2006, Journal of Neural Transmission.

[7]  W. Klein,et al.  Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.

[8]  P. Visser,et al.  Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer’s disease? , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  J. Wiltfang,et al.  Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease , 2005, Journal of Neural Transmission.

[10]  K. Blennow.  CSF biomarkers for mild cognitive impairment , 2004, Journal of internal medicine.

[11]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[12]  L. Baxter,et al.  Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele , 2004, Neurology.

[13]  Simon Lovestone,et al.  Is MCI really just early dementia? A systematic review of conversion studies , 2004, International Psychogeriatrics.

[14]  F. Lalonde,et al.  Context-specific memory and apolipoprotein E (ApoE) ε4: Cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease , 2004, Journal of the International Neuropsychological Society.

[15]  J. Kulisevsky,et al.  Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging , 2003, International journal of geriatric psychiatry.

[16]  K. Blennow,et al.  CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry , 2003, Brain Research Bulletin.

[17]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[18]  Kaj Blennow,et al.  Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients , 2003, Neuroscience Letters.

[19]  L. Wahlund,et al.  Mild cognitive impairment: experience from a memory clinic , 2003, Acta neurologica Scandinavica. Supplementum.

[20]  O. Almkvist,et al.  Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease , 2003, Acta neurologica Scandinavica. Supplementum.

[21]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[22]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[23]  E. Kaplan,et al.  The Boston naming test , 2001 .

[24]  K. Blennow,et al.  Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.

[25]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease , 2000, Neuroscience Letters.

[26]  T. Lehtimäki,et al.  Longitudinal stability of CSF tau levels in Alzheimer patients , 1999, Biological Psychiatry.

[27]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[28]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[29]  E. Matsubara,et al.  Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease , 1999, Neuroscience Letters.

[30]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[31]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan , 1998 .

[32]  K. Blennow,et al.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[33]  P. Milner,et al.  Preconceptions and prerequisites: Understanding the function of synaptic plasticity will also depend on a better systems-level understanding of the multiple types of memory , 1997, Behavioral and Brain Sciences.

[34]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[35]  L. Wahlund,et al.  Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele ϵ4 during 14 months follow-up , 1996, Neuroscience Letters.

[36]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[37]  L. Bäckman,et al.  Episodic memory functioning in a community-based sample of old adults with major depression: utilization of cognitive support. , 1994, Journal of abnormal psychology.

[38]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[39]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[40]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[41]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .

[42]  D. Wechsler.  WAIS-R manual : Wechsler adult intelligence scale-revised , 1981 .